ABOUT US/ Team / Board of Directors
Manel Cascalló Manel Cascalló, PhD – Board Chairman
Dr Cascalló is an expert in oncolytic therapies and gene therapy, a field in which has been involved from his PhD. Author of many original scientific papers and reviews in peer-reviewed journals, he is co-inventor of 5 patents on the use of adenovirus as antitumoral agents. He has been a researcher at the University of Barcelona (Spain), at the MD. Anderson Cancer Center de Houston (Houston, USA), at Merck Farma y Química (Barcelona, Spain), and since 2001 at the Virotherapy Group of the Intitut Català d'Oncologia (ICO) – IDIBELL. During his professional career Dr. Cascalló has always been focused in the development of new biotechnological agents for cancer treatment where he has lead different multidisciplinary teams. He possesses a solid expertise in Regulatory Affairs in Gene Therapy and has acted as Expert for the European Medicines Agencies (EMA). Additionally Dr. Cascalló is Member of the Biosafety Committee at IDIBELL where he is actively involved in the supervision of research protocols and provides advice in biosafety-related issues. Dr. Cascalló has also received formation in the management of Biotechnological Companies by the University of Cambridge (UK), and posseses a solid basis in Executive Management by the internationally recognized IESE Business School.

Dirk Büscher Dirk Büscher, PhD., MBA,
Board Member

Dr. Büscher holds a PhD in Biology, from the University of Hannover, Germany, and obtained an International Executive MBA from the Instituto de Empresa, Madrid. He received his PhD in Immunology, and focused his postdoctoral work at the Salk Institute, La Jolla, California, on molecular developmental biology and stem cell research. In 2004 he joined Cellerix SA, a Madrid-based cell therapy company, and from 2007 on occupied the position of Vice President of R&D. He had been in charge of the preclinical and CMC program of Cellerix, and represented the company in several scientific advices at EMA. Dirk Büscher is inventor on several patents related to stem cell technology. He further has served as industry expert on mesenchymal stem cells in internal EMA workshops
In 2010 he accepted a position as chief executive officer of Gri-Cel, a newly created subsidiary of Grifols, Barcelona, dedicated to advanced therapies and innovative therapeutic approaches. He currently serves on two boards of biotech companies, in which Grifols holds a significant participation.

Jose Terencio Jose Terencio, PhD
Board Member

Dr. Terencio holds a Master in R+D of Drugs by the University of Navarra, a PhD in CNS Pharmacology by the University of Barcelona, as well as a Development Management Program (PDD) by IESE Business School. He has more than 17 years of experience in the Biopharmaceutical industry holding several positions. Before joining Grifols, he was in charge of the Biochemistry and Molecular Biology Department in the Drug Discovery Area for Grupo Ferrer. In 2008 he was appointed at Grifols as R+D Director of one of the subsidiaries, Laboratorios Grifols. Two years later, he became the COO at Gri-Cel, a new subsidiary of Grifols aimed to invest in advanced therapies as well as innovative therapeutic approaches.

During his professional career, Dr. Terencio has worked in several therapeutic areas, CNS, Cardiovascular, Oncology and Infectious Diseases. His main scientific expertise is within the field of Drug Discovery and Development of Small Molecules. In the last few years, as COO of Gri-Cel his focus has moved into the assessment and management of projects involving Biotech companies, specifically those related with innovative therapies.

David Ian Bell David Ian Bell
Board Member

Mr. David Ian Bell is the Chief Innovation Officer for Grifols S.A. Additionally, he is the President and Chief Executive Officer of Grifols Innovation and New Technology Limited (GIANT). He also serves as General Counsel with responsibility for, among other things, mergers and acquisitions and new business development. Mr. Bell serves on Grifols Corporate, Bioscience, Diagnostic and Hospital Executive Committees and is on the Board of Directors of numerous Grifols’ portfolio companies including Alkahest, Aradigm, Singulex, and Araclon. Prior to joining Grifols in 2003, Mr. Bell served as General Counsel and Vice President of Alpha Therapeutic Corporation following more than 20 years as a corporate lawyer specializing in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Irvine focusing on Psychobiology (Neuroscience), Southwestern University School of Law and a postgraduate program at Harvard Law School.

Jaume Amat Jaume Amat
Board Member

Telecommunications engineer. A graduate of La Salle University, Jaume Amat i Riera entered the biotechnology sector through the young pioneering biotechnology company Archivel Technologies, specialised in seeking biotechnology solutions for the industrial sector and managing R+D+I projects, focusing in particular on analysis of the industrial application of developed technologies. He was a member of the founder team of Archivel Farma in 2005 and held the position of Chief Executive and Operating Officer (CEO and COO) between 2005 and 2009. In addition to his work at Archivel Technologies and Archivel Farma, in 2002 he contributed to the creation of Laboratorios Argos (acting as director until 2005) and Argos Acompanyament Adaptat, a pioneering Spanish service-based company involved in transporting and assisting people with reduced mobility.

Over the past few years, Mr. Amat has participated in various programs designed for executives, including Management Development Program (PDD-1-2009) at the IESE Business School, a motivation and leadership course at the University of Auckland Business School, as well as business development and strategic negotiation programmes at the Executive idEC, Universitat Pompeu Fabra.